AMGN vs GILD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMGN shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Mixed signals with both opportunities and risks present.
GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.
Compare Another Pair
Related Comparisons
AMGN vs GILD: Head-to-Head Comparison
This page compares Amgen Inc. (AMGN) and Gilead Sciences, Inc. (GILD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.